Stockscreener 앱 받기
11.92
7.09%
-0.91
시간 외 거래:
11.92
Arcturus Therapeutics Holdings Inc 주식(ARCT)의 최신 뉴스
Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline - Yahoo Finance
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking After Shares Rocket 41% - simplywall.st
Brokerages Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) PT at $59.20 - Defense World
Sumitomo Mitsui Trust Group, Inc. Reduces Stake in Arcturus Ther - GuruFocus
Legal & General Group Plc Has $410,000 Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
LPL Financial LLC Has $195,000 Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Wells Fargo & Company MN Acquires 7,785 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Can The Upcoming Catalysts Breathe New Life Into Arcturus Therapeutics? - RTTNews
Geode Capital Management LLC Has $9.42 Million Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress - ADVFN
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025 - Business Wire
Long Term Trading Analysis for (ARCT) - news.stocktradersdaily.com
JPMorgan Chase & Co. Has $4.01 Million Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Research Analysts Set Expectations for ARCT Q1 Earnings - American Banking and Market News
Q1 Earnings Estimate for ARCT Issued By Leerink Partnrs - Defense World
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine (PR Newswire) - Aktiellt
Vanguard Group Inc. Grows Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate - MSN
KLP Kapitalforvaltning AS Acquires New Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
HC Wainwright Reiterates Buy Rating for Arcturus Therapeutics (NASDAQ:ARCT) - Defense World
High Growth Tech Stocks To Watch In The US April 2025 - simplywall.st
Arcturus Therapeutics (ARCT) Gains FDA Fast Track for Influenza Vaccine - GuruFocus
Arcturus Therapeutics (ARCT) Receives Fast Track Status for Infl - GuruFocus
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation f - GuruFocus
Guggenheim Lowers Price Target for Arcturus Therapeutics (ARCT) Amid Risk Adjustments | ARCT Stock News - GuruFocus
Arcturus wins FDA fast track status for influenza vaccine - MSN
Arcturus wins FDA fast track status for flu shot (ARCT:NASDAQ) - Seeking Alpha
Arcturus Therapeutics Says FDA Granted Fast Track Designation to Potential H5N1 Vaccine - marketscreener.com
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1 - Business Wire
Breakthrough: FDA Fast-Tracks Revolutionary mRNA Vaccine Against Deadly H5N1 Pandemic Flu - Stock Titan
Commonwealth Equity Services LLC Reduces Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $59.20 Consensus Price Target from Brokerages - Defense World
(ARCT) Investment Report - news.stocktradersdaily.com
(ARCT) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Bank of New York Mellon Corp Sells 22,024 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Is Arcturus Therapeutics (ARCT) a Worst High-Risk High-Reward Growth Stock to Buy? - Insider Monkey
Benign Growth For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Underpins Stock's 26% Plummet - simplywall.st
Arcturus up 9% as phase 2 dosing begins for mRNA asset for cystic fibrosis - MSN
William Blair Issues Pessimistic Outlook for ARCT Earnings - Defense World
(ARCT) Proactive Strategies - news.stocktradersdaily.com
Arcturus Therapeutics Holdings Inc to Host Earnings Call - ACCESS Newswire
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $61.40 Average PT from Analysts - Defense World
Arcturus Therapeutics at Leerink’s Conference: mRNA Innovations and Strategic Plans - Investing.com UK
Despite Revenue Setback, Arcturus Therapeutics (ARCT) Vaccine Breakthroughs Fuel Optimism - markets.businessinsider.com
Arcturus Therapeutics (NASDAQ:ARCT) Given New $68.00 Price Target at Canaccord Genuity Group - Defense World
Analysts Have Lowered Expectations For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) After Its Latest Results - Simply Wall St
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo
HC Wainwright Lowers Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $60.00 - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Earns Overweight Rating from Cantor Fitzgerald - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2024 Earnings Call Transcript - Insider Monkey
Arcturus Therapeutics stock hits 52-week low at $14.3 By Investing.com - Investing.com Australia
Beyond The Numbers: 8 Analysts Discuss Arcturus Therapeutics Stock - Benzinga
Arcturus Therapeutics stock hits 52-week low at $14.3 - Investing.com India
0.39%
3.66%
자본화:
|
볼륨(24시간):